Elsevier

Clinica Chimica Acta

Volume 421, 5 June 2013, Pages 230-235
Clinica Chimica Acta

The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer

https://doi.org/10.1016/j.cca.2013.03.013Get rights and content

Highlights

  • We assessed the diagnostic value of apoE for malignant pleural effusion in NSCLC.

  • apoE levels are significantly increased in the pleural effusion of NSCLC, especially in adenocarcinoma pleural effusion.

  • apoE can be a potential tumor marker for malignant pleural effusion in NSCLC.

Abstract

Background

Apolipoprotein E (apoE) levels have been shown to be elevated in pleural effusion of patients with non-small cell lung cancer (NSCLC). However, the diagnostic value of apoE in pleural effusion in NSCLC has not been well validated and established.

Methods

Samples of malignant pleural effusions (MPE) and benign effusions were collected and analyzed for apoE, tumor markers, and other biochemical changes.

Results

ApoE levels were significantly higher in MPE (n = 160) than in benign pleural effusions (n = 40). They were higher in adenocarcinoma-associated MPE than in squamous cell carcinoma- and large cell carcinoma-associated MPE. The receiver operating characteristic curve showed that the sensitivity and specificity of apoE for the diagnosis of MPE were 87.5% and 85.3%, respectively, at the cutoff 105 ng/ml, and the area under the curve (AUC) was 0.748. For the diagnosis of adenocarcinoma-associated MPE, apoE achieved sensitivity and specificity of 70.8% and 83.30%, respectively, and the AUC was the highest of all the markers.

Conclusions

ApoE levels are significantly increased in the pleural effusion of patients with NSCLC. Increased concentration of apoE in a pleural effusion is a potential marker for the diagnosis of MPE as well as for differential diagnosis of MPE in NSCLC.

Introduction

Lung cancer has the highest mortality of all cancers, and its incidence is gradually increasing [1]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80% of all lung cancer cases, and includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Despite substantial improvements in surgical resection, chemotherapy, and radiation therapy, patients with lung cancer remain extremely vulnerable to relapse and death [2]. The cure rate of lung cancer is very low, and the average 5-year survival rate of patients with this cancer is < 15% [3], [4], [5], [6]. Patients with NSCLC often develop a malignant pleural effusion (MPE), which contains proteins from the circulation or from local inflammation or release of epithelial cells [7].

A pleural effusion is an abnormally large volume of fluid around the lung resulting from any of a number of medical conditions. A pleural effusion can be malignant or benign. Benign pleural effusion results from conditions such as tuberculosis or pneumonia, while MPE results from lung cancer and other cancers of the thorax. A cytologic test is the standard basis for diagnosis of MPE, but the positivity rate in known MPE varies considerably (from 11% to 78%) [8]. Thoracoscopy can greatly improve diagnostic sensitivity (90%) [9], but it has a high cost and is associated with injury and other complications and thus is limited in its clinical application.

While cytologic testing is the standard for diagnosis of MPE, it is also laborious and time-consuming. Because the cytologic testing can be sometimes subjective and the positivity rate varies [8], a more reproducible and specific test is needed to improve the diagnostic accuracy. A surrogate biochemical marker that allows differentiation of MPE in NSCLC from pleural effusion due to other diseases would be helpful in guiding and monitoring therapy as well as predicting prognosis. Efforts have been made to find markers that would improve the positivity rate in MPE, including tumor markers. Tumor markers are molecules secreted from tumor cells or produced by the host in response to cancer during the course of cancer genesis, development, invasion, and metastasis. These molecules are released into the blood or pleural effusion; in fact, their concentrations in pleural effusion may be much higher than in serum [10]. Tumor markers can be measured easily and quickly on automated analyzers.

Apolipoprotein E (apoE) is an important plasma lipoprotein that controls transportation and metabolism of cholesterol. It is well known that diseases such as atherosclerosis and Alzheimer disease are associated with different phenotypes and genotypes of abnormal apoE function [11], [12]. Overexpression of apoE has been shown to be related to cancer [13], [14], [15]. Moreover, apoE levels were found to be elevated in pleural effusions of patients with NSCLC [16], [17]. A recent study demonstrated that apoE expression was increased more frequently in lung cancer tissues of patients with MPE-associated lung adenocarcinoma than in those with lung adenocarcinoma or squamous cell carcinoma without MPE, suggesting that there is correlation between apoE and lung adenocarcinoma-associated MPE [18]. However, only limited data are available regarding the value of apoE in diagnosis of NSCLC-associated pleural effusion. Moreover, the diagnostic sensitivity and specificity of apoE in pleural effusion associated with NSCLC have not been well established. In this study, we aimed to determine the clinical role and laboratory diagnostic value of pleural fluid apoE in providing a more reliable and fast diagnosis of MPE in NSCLC, which would assist in guiding and monitoring therapy as well as predicting the course of the disease.

Section snippets

Participants

Pleural effusion specimens were prospectively collected from 200 patients with lung disease who presented at the First Affiliated Hospital of Wenzhou Medical College, China, between April 2011 and January 2012. Of the 200 patients, 160 were shown to have MPE from NSCLC diagnosed by histologic and immunohistologic analyses. The baseline demographic characteristics of these patients are summarized in Table 1.

The other 40 patients had benign pleural effusion resulting from a disease such as

apoE levels in MPE and benign pleural effusions

Glucose and protein levels were distributed normally, whereas other parameters were not normally distributed as determined by the Shapiro–Wilk test. Differences in age and sex distributions among the groups were not statistically significant (Table 2, Table 3). The median apoE concentration in MPE was 52.5 ng/ml (0.5–414.5 ng/ml), which was higher than that in benign pleural fluid. Levels of CEA, CY211, and protein in MPE were significantly higher than those in benign pleural effusions (Table 2

Discussion

Since the treatment approach and prognosis are distinctly different, it is extremely important to differentiate benign pleural effusion from MPE. Cytologic and pathologic evaluations are the reference standard for distinguishing benign pleural effusion from MPE, but these methods lack sensitivity. In searching for a marker of MPE that might offer greater diagnostic sensitivity, we examined the expression of apoE in pleural effusions. The level of apoE in MPE was significantly higher than that

Acknowledgments

This work was supported by the funds from Wenzhou Municipal Science and Technology Bureau, China (Y20110041).

References (20)

  • D.J. Stewart

    Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer

    Crit Rev Oncol Hematol

    (2010)
  • W.P. Su et al.

    Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer

    Lung Cancer

    (2011)
  • A. Jemal et al.

    Cancer statistics

    CA Cancer J Clin

    (2005)
  • C. Gridelli et al.

    Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents

    Oncogene

    (2003)
  • C.H. Chen et al.

    VEGFA Upregulates FLJ10540 and Modulates Migration and Invasion of Lung Cancer via PI3K/AKT Pathway

    PLoS One

    (2009)
  • E. Ogawa et al.

    Perimembrane aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC)

    Ann Surg Oncol

    (2008)
  • B. Rachet et al.

    Cancer survival in England and Wales at the end of the 20th century

    Br J Cancer

    (2008)
  • D.Y. Bell et al.

    Plasma proteins of the bronchoalveolar surface of the lungs of smokers and nonsmokers

    Am Rev Respir Dis

    (1981)
  • R. Braunschweig et al.

    Detection of malignant effusions: comparison of a telomerase assay and cytologic examination

    Diagn Cytopathol

    (2001)
  • A. Goyal et al.

    Oesophageal atresia and tracheo-oesophageal fistula

    Arch Dis Child Fetal Neonatal Ed

    (2006)
There are more references available in the full text version of this article.

Cited by (23)

  • Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine

    2019, Translational Oncology
    Citation Excerpt :

    ApoE has been the focus of intense interest with regard to immunomodulation as well as cancer for more than three decades. Despite that, there is still a lack of consensus on the role of ApoE in various cancers, overexpression of ApoE resulting in elevated levels in the serum, plasma or urine is associated with a poor prognosis or advanced stage in human cancers, including lung [8–10], gastric [11,12], ovarian [13,14] and bladder cancer [15,16]. On the contrary, ApoE was also shown to act as a direct metastasis-suppressive factor in melanoma [17], identifying ApoE as a potential biomarker for assessing tumor stage, metastasis, prognosis or response to treatment.

  • Pleural fluid biochemical analysis: The past, present and future

    2023, Clinical Chemistry and Laboratory Medicine
  • Apolipoproteins: New players in cancers

    2022, Frontiers in Pharmacology
View all citing articles on Scopus
1

These authors contributed equally to this work.

View full text